Reslizumab is a humanized interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), produced by recombinant DNA technology in murine non-secretory myeloma 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophil markers. Elevated levels of eosinophils increase the risk of exacerbation of asthma, including allergic and non-allergic forms of asthma characterized by eosinophilia. By targeting IL-5 and disrupting its signaling pathway, reslizumab aims to inhibit the maturation of eosinophils and promote programmed cell death. Reslizumab is sold as Cinqaero in Europe.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company
Your cart is currently empty.